Paul Martin, PhD, principal investigator in the Center for Gene Therapy, will receive funding from The Research Institute as the latest recipient of the Technology Development Fund. Dr. Martin has created a monoclonal antibody that binds Aβ amyloid and inhibits Aβ aggregation into amyloid plaques. Under the funding, he will conduct additional in vitro and in vivo experiments to demonstrate the efficacy of the use of this antibody as a potential passive immunotherapy for Alzheimer’s disease.
The Technology Development Fund is an internal funding program created to further develop inventions/intellectual property in order to make them more attractive and less risky to potential licensing and business partners.
An Ongoing Funding Opportunity
Two awards are given per year with awardees potentially receiving up to a maximum of $50,000 per year. Next deadline is Monday, April 4, 2011. To be eligible for the April deadline, faculty and staff must have filed an Invention and/or Intellectual Property Disclosure form with the Office of Technology Commercialization 30 days prior. A disclosure form can be found at www.NationwideChildrens.org/Technology-Commercialization.